ReviewJBMR plus2023
Pathophysiology of Medication-Related Osteonecrosis of the Jaw-A Minireview.
Review in JBMR plus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Serum vitamin D Levels in patients with medication-related osteonecrosis of the jaw: a systematic review and meta-analysis.BMC oral health · 2026Pooled it
- Platelet-Rich Fibrin in Surgical Wound Healing of Medication-Related Osteonecrosis of the Jaw: A Pilot Clinical Study.International journal of molecular sciences · 2026Trial
- Periodontitis and Glycaemic Dyscontrol Substantially Increase the Risk of Medication-Related Osteonecrosis of the Jaw: A Preclinical Study in Female Rats.Journal of clinical medicine · 2026Article
- Management of severe bone loss in patients at risk of medication-related osteonecrosis of the jaw with microsurgery and guided bone regeneration: A case study.Clinical advances in periodontics · 2026Article
- Mechanism-Oriented Biomaterial Strategies for Bone Regeneration in BRONJ: From Pathological Barriers to Evidence-Matched Repair.Biomolecules · 2026Review
- Clinical Characteristics and Serum Vitamin D Levels in Patients with MRONJ Associated with Antiresorptive Therapy: A Retrospective Study.Medicina (Kaunas, Lithuania) · 2026Article
- CT-Based Lesion Volume as an Independent Predictor of Surgical Recurrence in Medication-Related Osteonecrosis of the Jaw: A Multi-Center Study of 1007 Patients.Journal of clinical medicine · 2026Article
- Review
- Review
- Post-COVID-19 Jaw Osteonecrosis: A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Pentoxifylline and Tocopherol for the Management of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Retrospective Clinical Audit.Antibiotics (Basel, Switzerland) · 2026Article
- Graphene-Based 3D Scaffolds in Bone Regeneration: Emerging Opportunities for MRONJ Treatment.Pharmaceutics · 2026Review
- Label-free saliva screening platform using M13 bacteriophage-based 3D plasmonic structures for MRONJ diagnosis.Scientific reports · 2026Article
- Rescuing Mitochondrial Dysfunction in Macrophages Prevents Osteonecrosis of the Jaw in Anti-Resorptive Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Advanced biomaterial-based approaches for medication-related osteonecrosis of the jaw.Open life sciences · 2026Article
- Integrative Transcriptomic and Machine-Learning Analysis Reveals Immune-Inflammatory and Stress-Response Alterations in MRONJ.International journal of molecular sciences · 2025Article
- Mesenchymal Stem Cells in Socket Healing and MRONJ.Orthodontics & craniofacial research · 2025Review
- Stage-related changes of bone density and volume in treatment of medication-related osteonecrosis of the jaw.Scientific reports · 2025Article
- Imbalance of Serum Bone-Metabolism-Related Factors Associated with Osteonecrosis of the Jaw.Biomedicines · 2025Article
- Prevalence of Osteonecrosis of the Jaw Following Tooth Extraction in Patients with Osteoporosis: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse effect of antiresorptive medications administered for control of osseous malignancy, osteoporosis, or other bone metabolic diseases. Despite being reported in the literature two decades ago, MRONJ etiology, pathophysiology, and progression remain largely unknown, and current nonoperative or operative treatment strategies are mostly empirical. Several hypotheses that attempt to explain the mechanisms of MRONJ pathogenesis have been proposed. However, none of these hypotheses alone is able to capture the complex mechanistic underpinnings of the disease. In this minireview, we aim to highlight key findings from clinical and translational studies and propose a unifying model for the pathogenesis and progression of MRONJ. We also identify aspects of the disease process that require further investigation and suggest areas for future research efforts toward calibrating methodologic approaches and validating experimental findings. © 2023 The Authors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.